Akari Therapeutics (AKTX) Total Liabilities (2011 - 2026)

Akari Therapeutics' Total Liabilities history runs 16 years deep, the most recent figure standing at $19.5 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 33.22% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $19.5 million (down 33.22% YoY), while the FY2025 annual figure was $19.6 million, down 30.95% from the prior year.
• Total Liabilities came in at $19.5 million for Q1 2026 at Akari Therapeutics, roughly flat from $19.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $29.2 million in Q1 2025 to a low of -$6.6 million in Q1 2023.
• A 5-year average of $12.0 million and a median of $9.1 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 218.78% in 2023 and surged 4526.29% in 2024, its largest moves.
• Akari Therapeutics' Total Liabilities stood at $12.0 million in 2022, then tumbled by 61.93% to $4.6 million in 2023, then surged by 518.08% to $28.3 million in 2024, then slumped by 30.95% to $19.6 million in 2025, then retreated by 0.28% to $19.5 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $19.5 million, $19.6 million, and $22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison